Soluble p185(HER-2) in patients with malignant bone tumours.
BACKGROUND
This study was initiated to test the hypothesis that soluble p185(HER-2) could be of value as a diagnostic or predictive marker for patients with malignant bone tumours.


METHODS
Sera of 35 patients with high-grade malignant osteosarcoma (n = 27) and Ewing Sarcoma (n = 8) were tested at the time of diagnosis by ELISA and compared with sera of controls (n = 38) and clinical data.


RESULTS
In patients with osteosarcoma and Ewing Sarcoma, levels of sp185(HER-2) did not differ significantly from levels in controls. These results were irrespective of the type of tumour, survival chemotherapy or other clinical variables.


CONCLUSIONS
p185(HER-2) serum levels do not appear to be of diagnostic or predictive value for differentiation of high-grade osteosarcoma and Ewing Sarcoma.
Holzer
G
G
Department of Orthopaedics, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. gerold.holzer@meduniwien.ac.at
Pfandlsteiner
T
T
Koschat
M
M
Noske
H
H
Trieb
K
K
Kotz
R
R
D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000097:blood*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*; D012512:Sarcoma, Ewing / Q000097:blood*
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases